Melanoma Pathway Redesign
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Case studies outlining pathway redesign or service optimisation can be a valuable resource to support improvement in melanoma patient pathways and healthcare delivery in the adjuvant setting, taking into consideration current capacity and workforce constraints.
The three case studies shown here provide insights into the considerations and processes behind redesigning melanoma healthcare pathways, highlighting solutions implemented by centres and their recommendations of how to incorporate adjuvant melanoma therapy into the treatment pathway.
The case studies have been developed from discussions with key healthcare professionals from the melanoma multidisciplinary team in each of the centres, who shared their experiences, what helped them achieve success in pathway redesign and what learnings they would share to those attempting the same process.
Three different centres who specialise in oncology were chosen to reflect different geographies and ways of working.
These case studies were developed alongside healthcare professionals involved in the melanoma service. This project was funded by MSD. The Healthcare Professionals involved received honoraria for their input.
Summary
Summary of three case studies
- Guy’s & St Thomas’ NHS Foundation Trust
- The Christie NHS Foundation Trust
- The Clatterbridge Cancer Centre NHS Foundation Trust
The Guy’s & St Thomas’ NHS Foundation Trust Melanoma Service
Key takeaways and recommendations within the case study:
- A collaborative model of care was developed, run jointly by dermatologists, plastic surgeons and oncologists
- Mapping the process for the service is of value, to consider how any changes may impact individual clinics
- It is vital to communicate and educate all members of staff concerned
This is an MSD promotional resource for UK healthcare professionals only. This case study was developed alongside healthcare professionals involved in the melanoma service. It has been funded by MSD. Healthcare professionals involved received honorarium. The contents of the case studies reflect these healthcare professionals’ opinion and are not necessarily reflective of those of their Trust.
The Christie NHS Foundation Trust Melanoma Service
Key takeaways and recommendations within the case study:
- The service was nurse-led, with the protocol development, logistics and delivery being led by the treatment centre nurses
- Wide stakeholder engagement and ensuring awareness across the MDT is key to success
- Trial the service redesign with an initial team to identify any issues
This is an MSD promotional resource for UK healthcare professionals only. This case study was developed alongside healthcare professionals involved in the melanoma service. It has been funded by MSD. Healthcare professionals involved received honorarium. The contents of the case studies reflect these healthcare professionals’ opinion and are not necessarily reflective of those of their Trust.
The Clatterbridge Cancer Centre NHS Foundation Trust Oncology Toxicity Management Pathway
Key takeaways and recommendations within the case study:
- An immunotherapy management cycle was developed encompassing all phases of the patient pathway
- The pathway ensured any immunotherapy toxicities were quickly recognised and optimally managed
- Understanding the nuances and touchpoints in a toxicity pathway for uncomplicated and more complex patients is essential
This is an MSD promotional resource for UK healthcare professionals only. This case study was developed alongside healthcare professionals involved in the melanoma service. It has been funded by MSD. Healthcare professionals involved received honorarium. The contents of the case studies reflect these healthcare professionals’ opinion and are not necessarily reflective of those of their Trust.
KEYTRUDA® (pembrolizumab) as monotherapy is indicated for:
- The treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma
- The adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection.1
Please refer to the Summary of Product Characteristics and risk minimisation materials before making prescribing decisions.
Reference
- KEYTRUDA Summary of Product Characteristics.
Supporting documentation
Prescribing Information (Great Britain) and Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the EMC PI portal website.
